scholarly journals Do the acute lymphoblastic leukemia and non-hodgkin lymphoma patients have a worse prognosis of COVID-19 infection in children?: a case report

2021 ◽  
Vol 12 (1) ◽  
pp. 20-25
Author(s):  
Nadirah Rasyid Ridha ◽  
Bahrul Fikri ◽  
Rahmawaty Rahimi ◽  
Amiruddin Laompo ◽  
Conny Tanjung ◽  
...  

Background: Coronavirus Disease 2019 (COVID-19) is a contagious disease caused by a new type of Coronavirus namely Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Children with tumors or autoimmune diseases are more susceptible, because of suppression of their immune system, chemotherapy, radiotherapy, or surgery on tumors. Case presentation: We present the clinical features 3 Acute Lymphoblastic leukemia and 1 Non-Hodgkin lymphoma patients who were infected with COVID-19 since July to August 2020 in our hospital. These were the first four cases identified as COVID-19 positive in Dr Wahidin Sudirohusodo Hospital. Case 1, 2, and 4 were diagnosed as moderate and common type of COVID-19, while case 3 was classified as severe type. They may be transmitted COVID-19 infection during hospitalization. All cases were recovered from COVID-19 after a combination therapy against virus, bacteria, and also respiratory support. Conclusion: Our case series of four pediatric cancer patients showed a good outcome after prompt treatment, suggesting that malignancy in children may not be a contributor factor for COVID-19 recovery. Keywords: COVID-19; acute lymphoblastic leukemia; non-hodgkin lymphoma; children   Abstrak Latar belakang: Covid-19 (Coronavirus disease 2019) adalah penyakit menular yang disebabkan oleh Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Anak yang menderita kanker atau penyakit autoimun lebih rentan tertular karena penurunan system kekebalan tubuh, dampak kemoterapi, radioterapi, atau operasi tumor. Penyajian kasus: Kami melaporkan 3 pasien leukemia limfoblastik akut  dan 1 pasien limfoma non-Hodgkin yang terinfeksi Covid-19 sejak Juli-Agustus 2020. Kasus tersebut adalah 4 kasus pertama yang teridentifikasi Covid-19 di Rumah Sakit Dr. Wahidin Sudirohusodo. Kasus 1,2, dan 4 terdiagnosis positif Covid -19 derajat sedang, sedangkan kasus 3 tergolong berat. Mereka kemungkinan terinfeksi Covid-19 saat perawatan. Semua kasus dinyatakan sembuh dari Covid-19 setelah pemberian obat anti virus, antibiotik, dan alat bantu pernapasan. Kesimpulan: Serial kasus dari 4 pasien kanker anak dengan outcome yang baik setelah pengobatan yang cepat mengindikasikan bahwa penyakit keganasan pada anak kemungkinan bukan faktor yang berkontribusi dalam kesembuhan Covid-19. Kata kunci:  COVID-19; leukemia limfoblastik akut; limfoma non-hodgkin; anak    

2004 ◽  
Vol 42 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Tomasz Szczepa?ski ◽  
Gerard A.M. de Vaan ◽  
Auke Beishuizen ◽  
Jos� Bogman ◽  
Mieke W.J.C. Jansen ◽  
...  

2020 ◽  
Vol 4 (21) ◽  
pp. 5414-5424 ◽  
Author(s):  
Marcelo C. Pasquini ◽  
Zhen-Huan Hu ◽  
Kevin Curran ◽  
Theodore Laetsch ◽  
Frederick Locke ◽  
...  

Abstract Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world setting from a cellular therapy registry is presented here. As of January 2020, 511 patients were enrolled from 73 centers, and 410 patients had follow-up data reported (ALL, n = 255; NHL, n = 155), with a median follow-up of 13.4 and 11.9 months for ALL and NHL, respectively. Among patients with ALL, the initial complete remission (CR) rate was 85.5%. Twelve-month duration of response (DOR), event-free survival, and overall survival (OS) rates were 60.9%, 52.4%, and 77.2%, respectively. Among adults with NHL, the best overall response rate was 61.8%, including an initial CR rate of 39.5%. Six-month DOR, progression-free survival, and OS rates were 55.3%, 38.7%, and 70.7%, respectively. Grade ≥3 cytokine release syndrome and neurotoxicity were reported in 11.6% and 7.5% of all patients, respectively. Similar outcomes were observed in patients with in-specification and out-of-specification products as a result of viability <80% (range, 61% to 79%). This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.


Sign in / Sign up

Export Citation Format

Share Document